AllianceBernstein’s Achillion Pharmaceuticals ACHN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-1,093,199
Closed -$6.59M 3211
2019
Q4
$6.59M Buy
1,093,199
+899,799
+465% +$5.21M ﹤0.01% 1271
2019
Q3
$696K Sell
193,400
-20,700
-10% -$79.8K ﹤0.01% 2409
2019
Q2
$574K Buy
214,100
+17,200
+9% +$50.8K ﹤0.01% 2543
2019
Q1
$583K Sell
196,900
-1,400
-0.7% -$3.44K ﹤0.01% 2465
2018
Q4
$315K Buy
198,300
+13,200
+7% +$37.3K ﹤0.01% 2710
2018
Q3
$681K Hold
185,100
﹤0.01% 2504
2018
Q2
$524K Buy
185,100
+26,000
+16% +$88.6K ﹤0.01% 2593
2018
Q1
$590K Buy
159,100
+17,700
+13% +$57.9K ﹤0.01% 2473
2017
Q4
$407K Sell
141,400
-29,800
-17% -$108K ﹤0.01% 2598
2017
Q3
$769K Hold
171,200
﹤0.01% 2415
2017
Q2
$786K Sell
171,200
-12,200
-7% -$49K ﹤0.01% 2419
2017
Q1
$772K Sell
183,400
-16,963
-8% -$70.4K ﹤0.01% 2367
2016
Q4
$827K Buy
200,363
+163
+0.1% +$866 ﹤0.01% 2355
2016
Q3
$1.62M Hold
200,200
﹤0.01% 1930
2016
Q2
$1.56M Hold
200,200
﹤0.01% 1923
2016
Q1
$1.55M Buy
200,200
+1,860
+0.9% +$13.6K ﹤0.01% 1808
2015
Q4
$2.14M Sell
198,340
-3,360
-2% -$30.5K ﹤0.01% 1558
2015
Q3
$1.39M Sell
201,700
-3,460,382
-94% -$28.2M ﹤0.01% 1942
2015
Q2
$32.4M Buy
3,662,082
+37,751
+1% +$357K 0.03% 578
2015
Q1
$35.7M Buy
3,624,331
+3,458,131
+2,081% +$43.2M 0.03% 562
2014
Q4
$2.04M Sell
166,200
-25,000
-13% -$305K ﹤0.01% 1739
2014
Q3
$1.91M Hold
191,200
﹤0.01% 1757
2014
Q2
$1.45M Buy
191,200
+44,000
+30% +$176K ﹤0.01% 2012
2014
Q1
$484K Buy
147,200
+2,600
+2% +$9.1K ﹤0.01% 2444
2013
Q4
$480K Sell
144,600
-40,900
-22% -$119K ﹤0.01% 2463
2013
Q3
$560K Buy
185,500
+7,703
+4% +$52.8K ﹤0.01% 2414
2013
Q2
$1.45M Buy
+177,797
New +$1.36M ﹤0.01% 1844

AllianceBernstein's ACHN Position: Q1 2020 in Review

AllianceBernstein sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 1,093,199 shares — an estimated $6.59M sold.

AllianceBernstein first reported a position in ACHN in Q2 2013 and held it in 27 quarters. The position peaked at $35.7M in Q1 2015. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.

  • AllianceBernstein reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • AllianceBernstein sold 1,093,199 Achillion Pharmaceuticals shares in Q1 2020, an estimated $6.59M.
  • AllianceBernstein first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • AllianceBernstein's Achillion Pharmaceuticals position peaked at $35.7M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.

Based on AllianceBernstein's 13F filing for Q1 2020, filed 14 May 2020.